Apoptosis is dependent upon caspase activation leading to substrate cleavage and, ultimately, cell death. Although required for the apoptotic phenotype, it has become apparent that cells frequently die even when caspase function is blocked. This process, termed caspaseindependent cell death (CICD), occurs in response to most intrinsic apoptotic cues, provided that mitochondrial outer membrane permeabilization has occurred. Death receptor ligation can also trigger a form of CICD termed necroptosis. In this review, we will examine the molecular mechanisms governing CICD, highlight recent findings demonstrating recovery from conditions of CICD and discuss potential pathophysiological functions of these processes.
Definition and characteristics of caspase-independent cell death Apoptosis was originally defined by morphological criteria (Kerr et al., 1972) . Countless studies have since shown that apoptosis is inextricably linked with caspase activity; apoptotic pathways induce and require caspase function to bring about the orderly demise of a cell (Taylor et al., 2008) . We define caspase-independent cell death (CICD) as death that ensues when a signal that normally induces apoptosis fails to activate caspases. Even so, CICD often shares common characteristics with apoptotic cell death (Table 1 ). These include upstream signalling pathways that are critical for both forms of death such as mitochondrial outer membrane permeabilization (MOMP). Archetypal caspase-dependent events such as phosphatidylserine externalization and wide-scale chromatin condensation are notably absent during CICD. Cells undergoing CICD often display large-scale cytoplasmic vacuolization, autophagosome accumulation and peripheral nuclear condensation. In addition, CICD generally proceeds with much slower kinetics than apoptosis (Ekert et al., 2004) . Furthermore, although apoptotic cells exhibit a relatively invariant phenotype, cells undergoing CICD may display widely varying characteristics dependent upon factors such as the initial stimulus, cell type and so on.
Does caspase-independent cell death occur?
Our view is that the answer to this question is yes but with the proviso that it is not found in all animals. Genetic dissection of apoptosis signalling was begun using the nematode Caenorhabditis elegans as a model organism (Horvitz, 2003) . In C. elegans, CED-3 represents the sole executioner caspase. No death is observed in cells destined to undergo apoptosis when CED-3 function is abrogated (Ellis and Horvitz, 1986) . Therefore, CICD does not appear to occur in C. elegans. As far as it has been investigated, CICD rarely occurs in Drosophila melanogaster. Cells survive apoptosis induction in the absence of caspase activity in D. melanogaster (Fraser et al., 1997; Muro et al., 2006) . Although recent studies have demonstrated alternative cell death pathways occurring in C. elegans and D. melanogaster, these do not fall under our definition of CICD as they manifest in the absence of caspase inhibition (Abraham et al., 2007; Berry and Baehrecke, 2007) . The failure of cells, in both C. elegans and D. melanogaster, to undergo CICD is probably due to the absence of MOMP in these organisms (Varkey et al., 1999; Zimmermann et al., 2002) .
In higher eukaryotes, the existence of CICD is supported by findings in both cell culture models and studies utilizing mice deficient in apoptotic signalling. Several studies using cell lines have shown that CICD occurs typically by inducing apoptosis in the presence of chemical caspase inhibitors such as zVAD-fmk (Hirsch et al., 1997; Ohta et al., 1997; Sarin et al., 1997) . Alternatively, CICD can be observed following the induction of apoptosis in cells expressing genetically encoded caspase inhibitors such as XIAP, CrmA or p35 (Okuno et al., 1998; Denmeade et al., 1999; Wilkinson et al., 2004) . With respect to pharmacological or genetic means of caspase inhibition, the argument has been made that perhaps the degree of caspase inhibition was insufficient or did not neutralize all caspases, thereby permitting a low level of caspase activation to drive cell death. Moreover, some commonly used caspase inhibitors such as zVAD-fmk can exhibit off-target effects (Rozman-Pungercar et al., 2003; Misaghi et al., 2006) . Perhaps more definitively, CICD has been demonstrated in cells that lack components of the intrinsic apoptotic pathway such as Apaf-1, cytochrome c or caspase-9 Kuida et al., 1998; Li et al., 2000) . Analagous to the lack of CICD in lower organisms, CICD in higher eukaryotes often requires MOMP. This is perhaps best illustrated in one study that compared CICD in cells overexpressing Bcl-2 (blocking MOMP) or lacking Apaf-1. CICD was only observed in cells that had undergone MOMP (lacking Apaf-1) (Haraguchi et al., 2000) . However, as will be discussed further, there are examples of CICD that do not require MOMP.
Mice deficient in proteins required for caspase activation exhibit phenotypes consistent with the occurrence of CICD in vivo. Interdigital web loss is a characteristic apoptosis-dependent process that occurs during embryonic development. This process is signalled through the intrinsic apoptotic pathway requiring MOMP leading to apoptosome (Apaf-1/cytochrome c)-dependent activation of caspase-9. Importantly, genetic ablation of Apaf-1 slows but does not prevent interdigital web loss (Yoshida et al., 1998) . It is intriguing to note that the phenotype of mice lacking Bax and Bak (therefore unable to undergo MOMP) is much more severe than those unable to activate caspases downstream of MOMP (Apaf-1/caspase-9 null mice) (Lindsten et al., 2000) . This suggests that CICD can, at least partly, compensate for a lack of caspase-dependent apoptosis during development. Although supporting an in vivo role for CICD, mouse knockouts have also shown that CICD cannot fully compensate for a lack of apoptosis as mice lacking Apaf-1, caspase-9 or expressing non-apoptogenic cytochrome c frequently display pre-or perinatal lethality characterized by cleft palate and forebrain outgrowth (Cecconi et al., 1998; Hakem et al., 1998; Yoshida et al., 1998; Lindsten et al., 2000; Hao et al., 2005) . These phenotypes are consistent with a defect in cell death that presumably cannot be rescued by CICD. One caveat of this interpretation is that there is no evidence that the extra neurons observed in the forebrain have previously received a signal to die (for example, did they undergo MOMP). Another hypothesis that may account for this phenotype is that slower cell death (under conditions of CICD) leads to an overabundance of survival or growth signalling resulting in aberrant proliferation of neighbouring cells (Chipuk and Green, 2005) .
Collectively, these studies have convincingly demonstrated that diverse apoptotic stimuli can stimulate CICD. However, the question can be asked whether physiological CICD occurs. Some differentiated cell types, such as certain neuronal populations and cardiomyocytes, express low levels of Apaf-1 and might represent a physiological setting in which CICD occurs (Sanchis et al., 2003; Johnson et al., 2007) . Supporting this, several studies have shown that CICD occurs in cardiomyocytes and neurons following apoptotic stimulation (Stefanis, 2005; Bahi et al., 2006) . One study examining the removal of interdigital webs during limb bud development supports the physiological occurrence of CICD in vivo (Chautan et al., 1999) . Using morphological criteria and Apaf-1 null mice as a reference, these authors concluded that up to 10% of dying cells in the developing limb bud undergo CICD. Clearly, the occurrence of CICD in vivo requires further investigation. Such in vivo studies are hampered (as are those in cell culture) by the lack of readily available tools to easily detect MOMP and CICD. It is likely that during CICD, besides the lack of caspase activity, MOMP will occur under most circumstances. Cells undergoing CICD fail to expose 'eat-me' signals such as phosphatidylserine found on apoptotic cells. This should allow cells undergoing CICD to persist longer Caspase-independent cell death SWG Tait and DR Green in vivo thereby facilitating detection. Perhaps coupling fluorescent fusion proteins used to mark MOMP in cell culture such as cytochrome c-GFP with a means to rule out caspase activity will enable CICD detection in vivo (Goldstein et al., 2000) .
Means to an end: how cells die in the absence of caspase activity
Death receptor-induced necroptosis Apoptotic death receptor signalling is well elucidated. In short, following binding of their respective ligand, death receptors recruit intracellular adaptor molecules enabling dimerization and activation of caspase-8. Active caspase-8, in turn, drives the downstream apoptotic cascade (Lavrik et al., 2005) . Intriguingly, several studies have shown cell death in the absence of caspase activation following death receptor ligation ( Figure 1 ) (Jaattela and Tschopp, 2003) . Here, we use the term necroptosis to describe CICD induced by death receptors to distinguish this from MOMP-induced CICD, as the mechanisms of death are almost certainly distinct (Degterev et al., 2005) . Tumour necrosis factor (TNF) stimulation can induce necroptosis. One study found that in vivo treatment of mice with TNF and the caspase inhibitor z-VAD-fmk led to rapid death within 4 h (compared with 24 h when TNF is administered alone) (Cauwels et al., 2003) . Death was attributed to massive upregulation of reactive oxygen species as it was blocked by coadministration of antioxidants. Phospholipase A 2 (PLA 2 ) activation by TNF was a major contributor to reactive oxygen species production. PLA 2 undergoes caspasedependent cleavage during TNF-induced apoptosis. The authors' proposed model is that PLA 2 is activated following TNF treatment and under apoptotic conditions undergoes caspase cleavage, rendering PLA 2 and the necroptotic pathway non-functional. When caspase activity is inhibited, reactive oxygen species generation by PLA 2 contributes to necroptosis. One potential caveat of these studies is that zVAD-fmk can display some toxicity issues in vivo (Chauvier et al., 2007) . However, another study using CrmA to inhibit caspase activity has also demonstrated the occurrence of necroptosis following TNF treatment (Vercammen et al., 1998) .
Fas-induced apoptosis and necroptosis share some common molecular components. Fas-associated protein with death domain (FADD) acts as an essential adaptor molecule as it links death receptor oligomerization to caspase-8 activation. FADD is also required for necroptosis induced following Fas activation as loss of FADD expression blocks both Fas-induced apoptosis and necroptosis (Holler et al., 2000) . Furthermore, FADD oligomerization itself is sufficient to induce necroptosis (Kawahara et al., 1998) . However, FADD does not appear to be involved in TNF-induced necroptosis as no effect was observed following loss of FADD or overexpression of a dominant negative form (Holler et al., 2000) . Further dissection of death receptor-induced necroptosis has revealed a key function for receptor-interacting protein-1 (RIP-1). RIP-1, an intracellular adaptor molecule with kinase activity, has earlier been shown to be involved in recruiting the IkB kinase complex to the TNF receptor enabling nuclear factor-kB activation. Cells in which RIP-1 is lacking or in which RIP-1 kinase function is inhibited are refractory to necroptosis mediated by either TNF or Fas (Holler et al., 2000; Degterev et al., 2008) . In contrast to its function in nuclear factor-kB signal transduction, several studies have shown a requirement for RIP-1 kinase function in signalling necroptosis (Kelliher et al., 1998) . One possible mechanism by which RIP-1 can lead to necroptosis is by disrupting the interaction of the adenine nucleotide translocase with cyclophilin D. This, in turn, leads to mitochondrial dysfunction, although it remains unclear how RIP-1 signals to the mitochondrial inner membrane (Temkin et al., 2006 ).
An alternative means by which RIP-1 function could drive necroptosis has been suggested in a separate study (Yu et al., 2004) . In this study, it was found that reduction of caspase-8 function through RNA interference or by using zVAD-fmk induces necroptosis. This suggests that a low level of caspase-8 activity is required for cell viability. Necroptosis induction was dependent upon RIP-1 and JNK function and appeared to occur through macroautophagy (hereafter termed autophagy). Autophagy is a homoeostatic cellular process regulating protein and organelle turnover by lysosomal destruction (Levine and Kroemer, 2008) . Although inhibition of autophagy through RNAi inhibited immediate cell death, it was not examined whether these cells ultimately survived. Although there are putative links between death receptor signalling and autophagy, such as a molecular interaction between FADD and Atg5, it remains unclear as to whether an autophagic death pathway is driven by death receptors under conditions of necroptosis (Pyo et al., 2005) . Furthermore, the idea that autophagy, per se, can promote cell death remains an open question.
Mitochondria and CICD
Death receptor-induced necroptosis may be restricted to certain cell types. In stark contrast, CICD, under conditions where MOMP has occurred, appears nearly universal. Numerous studies have demonstrated that various MOMP-inducing stimuli trigger CICD in a wide variety of cell types. Furthermore, direct induction of MOMP through ectopic Bax expression is sufficient to induce death in the presence of caspase inhibitors (Xiang et al., 1996) . MOMP may contribute by one of several ways to bring about CICD. The main models by which MOMP can bring about CICD are either through a general decline in mitochondrial function and/or through the release of mitochondrial proteins that can actively induce CICD (Figure 2) .
Mitochondria have various critical cellular functions. Perhaps the most important function of mitochondria is the generation of ATP through the process of aerobic respiration. However, other mitochondrial functions such as the generation of acetyl CoA, nicotinamide adenine dinucleotide production and buffering intracellular calcium levels are also important. Under conditions of organelle damage, for example MOMP, some of these processes such as acetyl CoA generation for lipid biogenesis might be even more critical. Under apoptotic conditions, caspase-3 cleaves the p75 subunit of mitochondrial respiratory chain complex I. Cleavage of p75 leads to disruption of electron transport, loss of Dcm and reduction of ATP levels (Ricci et al., 2004) . However, under conditions of CICD, mitochondria gradually lose Dcm even though caspase-dependent cleavage of p75 is blocked (Colell et al., 2007) . Why this occurs is not clear but one reason may be a gradual release of respiratory chain components from the mitochondria following MOMP. Gradual loss of Dcm consequently leads to the loss of ATP generation and, ultimately, cell death independent of caspase activity. However, loss of ATP generation following MOMP most likely cannot account for CICD in transformed cells as they predominantly rely upon glycolysis for ATP generation. Besides ATP generation, maintenance of Dcm is required for mitochondrial protein import, loss of which is likely to impact on many different mitochondrial functions (Gasser et al., 1982) . The relative contribution of other MOMP-induced mitochondrial defects to CICD remains an open question.
Concurrent with MOMP, the mitochondrial network undergoes dramatic fragmentation. This is due to the increased rates of mitochondrial fission coupled with decreased fusion (Arnoult, 2007) . Mitochondrial fusion has been reported to have a protective function in cellular homoeostasis and enables cells to maintain a homogenous Dcm (Chen et al., 2003) . It is thought that fusion may achieve this by promoting mitochondrial complementation thereby restoring function to damaged mitochondria. It is unknown whether long-term disruption of mitochondrial morphology also contributes to CICD.
Mitochondrial outer membrane permeabilization leads to the release of cytochrome c from the mitochondrial intermembrane space (IMS). Besides cytochrome c, numerous IMS proteins such as Smac/Diablo, HtrA2/ Omi, Endonuclease G (Endo G) and apoptosis-inducing factor (AIF) are released Du et al., 2000; Verhagen et al., 2000; Li et al., 2001; Suzuki et al., 2001) . Various groups have proposed that these proteins can actively induce CICD following mitochondrial release.
Apoptosis-inducing factor, perhaps the best-studied example of a CICD mediator, is slowly released from mitochondria following MOMP in a caspase-independent manner although caspase activity may accelerate the release (Arnoult et al., 2003; Munoz-Pinedo et al., 2006) . Following release, AIF translocates to the nucleus. Various in vitro studies have shown that nuclear AIF mediates chromatin condensation and CICD . In vitro models of embryonic body cavitation suggested that AIF might have a function in cell death observed during cavitation; however, others have found no such effect in vivo (Joza et al., 2001; Brown et al., 2006) . It has become clear that AIF has an important function in aerobic respiration. For example, Harlequin mice (which contain a proviral insertion in the AIF gene) display an 80% reduction in AIF levels. These mice exhibit a phenotype in line with defects in mitochondrial respiratory problems including progressive neuronal and retinal degeneration (Klein et al., 2002) . Furthermore, cells lacking AIF are defective in electron transport chain complex I/III activity (Klein et al., 2002; Vahsen et al., 2004) . From these studies, it is clear that mitochondrial release of AIF following MOMP would compromise mitochondrial function. This strongly suggests that, rather than acting as a positive mediator of CICD, AIF release promotes CICD by contributing to loss of mitochondrial function. However, a recent study addressed the two functions of AIF using mitochondrially tethered forms of AIF. These AIF proteins were not released from the mitochondria following MOMP. The authors found that these tethered proteins could not rescue enhanced CICD observed in Apaf-1 null relative to Apaf-1/AIF null neurons, suggesting an active role for AIF during CICD (Cheung et al., 2006) . Ultimately, generation of knock-in mice using these or other approaches and crossing with mice deficient in intrinsic apoptosis signalling will reveal whether there is an in vivo role for nuclear AIF in mediating CICD.
Other mitochondrial IMS proteins that have been proposed to have a function in CICD include EndoG. EndoG is the predominant endonuclease of the mitochondrial IMS and is thought to be involved in regulating mitochondrial biogenesis, DNA synthesis and repair. Following MOMP, EndoG is released from the mitochondria whereupon it can translocate to the nucleus and, perhaps, induce DNA degradation . It is unclear as to whether EndoG is Cytochrome C
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Smac/Diablo EndoG Htr2A/Omi Figure 2 Mitochondrial roles in caspase-independent cell death. In the absence of caspase activity, following mitochondrial outer membrane permeabilization (MOMP), various mitochondrial intermembrane space proteins are released triggering loss of mitochondrial function and/or proactively contributing to cell death. Simultaneously, mitochondrial fission is activated and fusion inactivated thereby disrupting mitochondrial morphology. Collectively, these events contribute to caspase-independent cell death (CICD).
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involved in mediating CICD. Paradoxically, some studies have suggested that its release may require caspase activity (Arnoult et al., 2003) . However, this may not always be the case. For example, a recent study in ischaemic cardiomyocytes demonstrated EndoG release following MOMP in a caspase-independent manner (Bahi et al., 2006) . Revealingly, suppression of EndoG levels by RNAi had no effect on CICD.
HtrA2/Omi is a mammalian serine protease that resides in the mitochondrial IMS. Perhaps relevant to its primary function, HtrA2/Omi is evolutionarily conserved. Bacterial homologues exhibit chaperone activity (Vande Walle et al., 2008) . Following MOMP, HtrA2/ Omi is released into the cytoplasm whereupon it can interact with XIAP thereby promoting caspase activation during apoptosis (Suzuki et al., 2001) . A more relevant function of HtrA2/Omi in CICD is that it exhibits serine protease activity. Ectopic cytoplasmic expression of HtrA2/Omi is sufficient to induce cell death that is not inhibited by zVAD-fmk. However, in vivo studies have convincingly demonstrated that, rather than being involved in cell death, HtrA2/Omi function is required for normal mitochondrial homoeostasis. HtrA2/Omi null mice exhibit muscle wasting and neurodegeneration (Jones et al., 2003) . These are traits common to defects in mitochondrial physiology, in line with the function of HtrA2/Omi as a mitochondrial chaperone. Importantly, cells lacking HtrA2/Omi are more sensitive to cell death following stimulation with various stimuli arguing against a prodeath function for this protein.
Waking the dead: recovery from MOMP and resistance to CICD Mitochondrial outer membrane permeabilization has often been viewed as a point of no return as it appears to commit a cell to death regardless of caspase activity. However, as we will discuss further, this is not always the case.
Sympathetic neurons deprived of nerve growth factor undergo MOMP and apoptosis that can be blocked by inhibiting caspase function (Deshmukh and Johnson, 1998; Martinou et al., 1999) . Neurons typically express low levels of Apaf-1 protein and, as such, endogenous caspase inhibitors such as XIAP are at sufficient levels to block the ability of cytochrome c to induce apoptosis (Potts et al., 2003) . Nerve growth factor deprivation induces a so-called competence to die likely due, in part, to antagonism of XIAP function by Smac/Diablo or HtrA2/Omi released following MOMP (Deshmukh et al., 2002) . Importantly, re-addition of nerve growth factor under these circumstances effectively restores cell viability and therefore represents an example of recovery from CICD. It may be that similar recovery from CICD in vivo is responsible for the extra neurons and forebrain outgrowth observed in Apaf-1 and caspase-9 null mice. It is unclear as to the mechanism/s enabling neuronal recovery from CICD. Perhaps the increased glycolytic levels in neurons facilitate recovery. This would lessen the necessity for mitochondrial-dependent ATP production and mitigate the energy crisis that occurs following MOMP. However, this cannot be the sole factor determining recovery from CICD as many tumour cell lines that are highly glycolytic fail to recover from conditions of CICD.
In contrast to neurons, which are non-dividing, a recent study showed that proliferating cells can recover from conditions of CICD (Colell et al., 2007) . In this study, the authors employed a retroviral screen to identify proteins that could promote recovery from CICD. Using this approach, the authors found that glyceraldehyde-3-phosphate dehydrogenase (GAPDH) could effectively protect cells from CICD downstream of MOMP. GAPDH was shown to promote recovery dependent upon two functions. First, the well-characterized function of GAPDH in glycolysis was shown to be necessary. A second novel function of GAPDH in promoting autophagy was also described and required for cellular recovery. Under conditions of CICD, GAPDH participates in transcriptional upregulation of ATG12 and enhances autophagy. Under these circumstances, as appears generally the case, autophagy acts primarily as a protective stress response. Upregulation of autophagy enabled mitochondrial clearance leading the authors to speculate that perhaps autophagy was required to clear the cell of damaged mitochondria. Alternatively or additionally, autophagy may also have facilitated energy production by catabolic breakdown of cellular components.
Many key questions remain as to how cells can recover from CICD. One critical issue is from where the 'new' mitochondria arise. Two equally exciting possibilities exist: either 'MOMP-ed' mitochondria can effectively heal and re-seal their outer membrane or some mitochondria may evade MOMP thereby providing a seed population to repopulate the cell. How exactly GAPDH stimulates autophagy and what functions autophagy has during cellular recovery remain to be deciphered. Moreover, how autophagy specifically targets damaged mitochondria, if indeed it does, is largely undefined (Yu et al., 2008) . It is also likely that GAPDH represents only one of many mediators that enable recovery from CICD. Although technically challenging, means of assessing whether cells can recover from conditions of CICD in vivo should be sought.
CICD in disease and therapy
Aberrant levels of apoptosis have been linked with numerous diseases. For example, increased levels of apoptosis contribute to pathological damage observed following acute ischaemic damage in neuronal and cardiac tissues. Inhibition of apoptosis has multiple functions in tumorigenesis and in governing the sensitivity of tumour cells to conventional chemotherapies. Therefore, manipulating apoptosis obviously represents an attractive and much sought after therapeutic aim. It is also likely that pathways leading to CICD or recovery from CICD also represent therapeutic targets.
Cells are subject to ischaemia during neuronal stroke or cardiac infarction. Ischaemia, among other effects, typically induces an MOMP-dependent apoptotic programme leading to cell death (Chan, 2004; Gustafsson and Gottlieb, 2008) . If MOMP is considered as a point of no return, then one would expect that inhibition of caspases would afford no protective effect. However, several studies have shown that administration of caspase inhibitors can provide significant clinical efficacy in murine models of stroke (Balsam et al., 2005; Braun et al., 2007) . Taken at face value, this may indicate that cells destined to undergo apoptosis can effectively recover from CICD-inducing conditions. Perhaps an even better clinical outcome could be obtained through manipulation of metabolic pathways and/or enhancement of autophagy. However, as is the case for the extra neurons in the Apaf-1 or caspase-9 null mice, there is no proof that caspase inhibition during stroke enables cellular protection from CICD-inducing conditions. It remains possible that neurons dying under conditions of CICD perhaps release survival factors promoting survival in surrounding tissue. Furthermore, inhibition of other caspases that are primarily involved in inflammatory responses, such as caspase-1, may also provide a protective effect. A further caveat is that offtarget inhibition of other proteases, such as calpains, may account for the ability of certain caspase inhibitors to provide a neuroprotective effect (Waterhouse et al., 1998) .
Cells must evade apoptosis at multiple stages of the metastatic process for cancer to arise (Green and Evan, 2002) . Apoptosis barriers to tumour formation include apoptotic signals driven by growth-promoting oncogenes, detachment from the extracellular matrix and apoptotic signalling induced by a hypoxic low-nutrient environment. As such, cancer cells have developed numerous ways to inhibit apoptosis. Perhaps the best described is upregulation of antiapoptotic Bcl-2 family members thereby inhibiting MOMP (Chipuk and Green, 2008) . However, besides inhibition of MOMP, there is a growing body of evidence that caspase inhibition downstream of MOMP is a common event in multiple tumour types. This may support a role for recovery from CICD in promoting tumorigenesis. Moreover, if this is the case, it has implications for new therapies that solely rely on inducing MOMP as a means of killing tumour cells.
Several studies have shown loss of Apaf-1 expression in a variety of tumour cell lines. This was first described in metastatic melanoma in which Apaf-1 expression was lost due to the loss of promoter methylation (Soengas et al., 2001) . Downregulation of Apaf-1 expression in metastatic melanoma correlates with poor prognosis (Fujimoto et al., 2004) . Reduction of Apaf-1 expression has also been observed in other tumours such as acute myeloid leukaemias, cervical carcinoma and colorectal cancer, where low Apaf-1 levels correlate with disease progression (Jia et al., 2001; Leo et al., 2007; Zlobec et al., 2007) . Besides loss of Apaf-1 expression, tumour cells can inhibit apoptosome-dependent caspase activity in other ways. For example, the oncogenic Bcr-Abl kinase, besides inhibiting MOMP, can also block apoptosome activity by inhibiting caspase-9/Apaf-1 binding (Deming et al., 2004) . Other less well-defined means of inhibition of apoptosome activity have also been reported (Wolf et al., 2001) . Importantly, apoptosome function can also be modulated by other proteins, intracellular ion and nucleotide levels (Schafer and Kornbluth, 2006) . Under such conditions, levels of Apaf-1 or caspase-9 might be completely normal, whereas apoptosome function and caspase activity are compromised. Besides its well-characterized apoptotic function, a recent report demonstrated an apparent role for Apaf-1 in mediating DNA damage-induced cell cycle arrest (Zermati et al., 2007) . Loss of this alternative Apaf-1 function would also be expected to impact on tumorigenesis. Various tumours have been shown to overexpress the endogenous caspase inhibitor, XIAP, which dependent on tumour cell type can correlate with a poor prognosis (Tamm et al., 2004) . In addition, inhibition of XIAP function restores chemosensitivity in various tumour cell lines (Sasaki et al., 2000) . Besides its ability to inhibit caspases, XIAP also has alternative functions that may be relevant for tumorigenesis such as its function in transforming growth factor-b and nuclear factor-kB signalling (Yamaguchi et al., 1999; Lu et al., 2007) .
Collectively, these data indicate that tumour cells can inhibit caspase activation pathways downstream of MOMP and this might be physiologically relevant for both tumour progression and therapeutic sensitivity. As it appears that MOMP, in the absence of caspase activity, leads to CICD it is not unreasonable to predict that tumour cells can also recover from CICD. The discovery that GAPDH alone can promote recovery of proliferating cells under CICD-inducing conditions may be relevant for tumours (Colell et al., 2007) . Metastatic cells typically display high levels of GAPDH, glycolytic activity and autophagy, all of which were deemed necessary for recovery from CICD (Revillion et al., 2000; Degenhardt et al., 2006; Deberardinis et al., 2008) . Loss of Apaf-1 has been shown by some to promote transformation in vitro although this has been questioned by others (Soengas et al., 1999; Scott et al., 2004) . Another study has shown that expression of a dominant negative version of caspase-9 efficiently promotes tumorigenesis in a myc-driven model of lymphoma (Schmitt et al., 2002) . Finally, a recent study has shown that inhibition of clonogenic growth in a lung cancer cell line following chemotherapy could only be achieved by enhancing apoptosome activity. Evidently, these cells could survive and proliferate under conditions of CICD (Hoffarth et al., 2008) .
If cancer cells can block the intrinsic apoptosis pathway and recover from CICD what is the best way to kill them? At least in some situations autophagy and glycolysis appear essential for recovery from CICD. It may be that inhibiting these processes using already available autophagy inhibitors such as chloroquine and/ or glycolysis inhibitors, for example 2-deoxyglucose, will effectively block cellular recovery. Alternatively, attempts to restore apoptosome function under conditions of CICD might prove of therapeutic benefit.
Conclusion
Caspase-independent cell death is most likely engaged under physiological and pathological situations. However, understanding how cells actually die during CICD remains limited. In contrast to the study of apoptosis, there are limited means to detect CICD. More specifically, tools need to be developed to effectively discern CICD in vivo. The recent finding that cells can recover from conditions of CICD poses a number of key basic research questions. Moreover, this finding has clear implications for oncogenesis and the treatment of cancer. Accordingly, one might expect that apoptosis inducers coupled with drugs that block recovery from CICD might represent effective anti-cancer therapies.
